# Hypoxia-mimicked mitochondrial stress triggers APOBEC3A-mediated DNA damage via non-canonical innate immune activation

**Authors:** Rodolphe Suspène, Béibhinn O’Hora, Constance de Maere d’Aertrycke, Lydie Couturier, Théo Defresne, Pierre Khalfi, XiongXiong Li, Jean-Pierre Vartanian

PMC · DOI: 10.1093/narmme/ugag012 · NAR Molecular Medicine · 2026-02-03

## TL;DR

Hypoxia in tumors causes mitochondrial stress, which activates APOBEC3A and leads to DNA damage through a new immune-like pathway.

## Contribution

A novel interferon-independent pathway linking mitochondrial stress to APOBEC3A-mediated DNA damage is identified.

## Key findings

- Cobalt chloride induces APOBEC3A expression and DNA breaks in THP-1 cells.
- Mitochondrial dysfunction and mtDNA release activate RIG-I/TRAF6/NF-κB to drive A3A expression.
- RNA polymerase III inhibition reduces A3A levels and DNA damage, confirming the pathway's role.

## Abstract

Hypoxia is a hallmark of the tumour microenvironment, driving metabolic reprogramming, immune activation, and genome instability. Here, we showed that cobalt chloride (CoCl2), a hypoxia-mimicking agent, potently induces the expression of the DNA cytidine deaminase APOBEC3A (A3A) in THP-1, a human monocytic cell line. A3A upregulation occurred in a dose-dependent manner, independently of type I interferon signalling, and was accompanied by increased double-strand DNA breaks. Transcriptomic profiling revealed broad hypoxia-driven reprogramming, characterized by activation of the stress response and downregulation of mitochondrial signalling pathways. Mechanistically, cobalt chloride induced mitochondrial dysfunction, metabolic reprogramming, and cytosolic release of mitochondrial DNA (mtDNA). Cytosolic mtDNA was transcribed by RNA polymerase III into immunostimulatory RNA, which activated the RIG-I/TRAF6/NF-κB signalling cascade to drive A3A expression. Inhibition or knockdown of RNA polymerase III markedly reduced both A3A levels and DNA damage, highlighting the central role of this pathway. All together, our findings reveal a novel interferon-independent signalling route through which hypoxia-induced mitochondrial stress activates A3A, directly linking metabolic dysfunction to genome instability. This mechanism involves mitochondrial perturbation as a key driver of APOBEC3-mediated mutagenesis in hypoxic tumours and other diseases associated with mitochondrial stress.

Graphical Abstract

## Linked entities

- **Genes:** APOBEC3A (apolipoprotein B mRNA editing enzyme catalytic subunit 3A) [NCBI Gene 200315], RIGI (RNA sensor RIG-I) [NCBI Gene 23586], TRAF6 (TNF receptor associated factor 6) [NCBI Gene 7189], NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790]
- **Chemicals:** cobalt chloride (PubChem CID 24288)

## Full-text entities

- **Genes:** SLC40A1 (solute carrier family 40 member 1) [NCBI Gene 30061] {aka FPN, FPN1, HFE4, IREG1, MST079, MSTP079}, IL18 (interleukin 18) [NCBI Gene 3606] {aka IGIF, IL-18, IL-1g, IL1F4}, APOBEC3G (apolipoprotein B mRNA editing enzyme catalytic subunit 3G) [NCBI Gene 60489] {aka A3G, ARCD, ARP-9, ARP9, CEM-15, CEM15}, SLC39A14 (solute carrier family 39 member 14) [NCBI Gene 23516] {aka HCIN, HMNDYT2, LZT-Hs4, NET34, ZIP14, cig19}, IFNA1 (interferon alpha 1) [NCBI Gene 3439] {aka IFL, IFN, IFN-ALPHA, IFN-alphaD, IFNA13, IFNA@}, IKBKB (inhibitor of nuclear factor kappa B kinase subunit beta) [NCBI Gene 3551] {aka IKK-2, IKK-beta, IKK2, IKKB, IMD15, IMD15A}, RPL13 (ribosomal protein L13) [NCBI Gene 6137] {aka BBC1, D16S444E, D16S44E, L13, SEMDIST, eL13}, NFKBIA (NFKB inhibitor alpha) [NCBI Gene 4792] {aka EDAID2, IKBA, MAD-3, NFKBI}, CDA (cytidine deaminase) [NCBI Gene 978] {aka CDD}, IFNB1 (interferon beta 1) [NCBI Gene 3456] {aka IFB, IFF, IFN-beta, IFNB}, ARNT (aryl hydrocarbon receptor nuclear translocator) [NCBI Gene 405] {aka ARNT1, HIF-1-beta, HIF-1beta, HIF1-beta, HIF1B, HIF1BETA}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, RPL13A (ribosomal protein L13a) [NCBI Gene 23521] {aka L13A, TSTA1, uL13}, AIFM1 (apoptosis inducing factor mitochondria associated 1) [NCBI Gene 9131] {aka AIF, AUNX1, CMT2D, CMTX4, COWCK, COXPD6}, APOBEC3H (apolipoprotein B mRNA editing enzyme catalytic subunit 3H) [NCBI Gene 164668] {aka A3H, ARP-10, ARP10}, STING1 (stimulator of interferon response cGAMP interactor 1) [NCBI Gene 340061] {aka ERIS, MITA, MPYS, NET23, SAVI, STING}, SLC39A8 (solute carrier family 39 member 8) [NCBI Gene 64116] {aka BIGM103, CDG2N, LZT-Hs6, PP3105, ZIP8}, CYCS (cytochrome c, somatic) [NCBI Gene 54205] {aka CYC, HCS, THC4}, SERPINA13P (serpin family A member 13, pseudogene) [NCBI Gene 388007] {aka SERPINA13, UNQ6121}, APOBEC3C (apolipoprotein B mRNA editing enzyme catalytic subunit 3C) [NCBI Gene 27350] {aka A3C, APOBEC1L, ARDC2, ARDC4, ARP5, PBI}, TFAM (transcription factor A, mitochondrial) [NCBI Gene 7019] {aka MTDPS15, MTTF1, MTTFA, TCF6, TCF6L1, TCF6L2}, TLR9 (toll like receptor 9) [NCBI Gene 54106] {aka CD289}, MYD88 (MYD88 innate immune signal transduction adaptor) [NCBI Gene 4615] {aka IMD68, MYD88D, WM1}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, POTEF (POTE ankyrin domain family member F) [NCBI Gene 728378] {aka A26C1B, POTE2alpha, POTEACTIN}, AIM2 (absent in melanoma 2) [NCBI Gene 9447] {aka PYHIN4}, TRAF6 (TNF receptor associated factor 6) [NCBI Gene 7189] {aka MGC:3310, RNF85}, ANXA5 (annexin A5) [NCBI Gene 308] {aka ANX5, CPB-I, ENX2, HEL-S-7, PP4, RPRGL3}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, RELA (RELA proto-oncogene, NF-kB subunit) [NCBI Gene 5970] {aka AIF3BL3, CMCU, NFKB3, p65}, COX1 (cytochrome c oxidase subunit I) [NCBI Gene 4512] {aka COI, MTCO1}, IKBKE (inhibitor of nuclear factor kappa B kinase subunit epsilon) [NCBI Gene 9641] {aka IKK-E, IKK-i, IKKE, IKKI}, MAVS (mitochondrial antiviral signaling protein) [NCBI Gene 57506] {aka CARDIF, IPS-1, IPS1, VISA}, APOBEC3F (apolipoprotein B mRNA editing enzyme catalytic subunit 3F) [NCBI Gene 200316] {aka A3F, ARP8, BK150C2.4.MRNA, KA6}, H2AX (H2A.X variant histone) [NCBI Gene 3014] {aka H2A.X, H2A/X, H2AFX}, CGAS (cyclic GMP-AMP synthase) [NCBI Gene 115004] {aka C6orf150, D4, MB21D1, h-cGAS}, B2M (beta-2-microglobulin) [NCBI Gene 567] {aka AMYLD6, IMD43, MHC1D4}, TBK1 (TANK binding kinase 1) [NCBI Gene 29110] {aka AIARV, FTDALS4, IIAE8, NAK, T2K}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, APOBEC3A (apolipoprotein B mRNA editing enzyme catalytic subunit 3A) [NCBI Gene 200315] {aka A3A, ARP3, PHRBN, bK150C2.1}, BAK1 (BCL2 antagonist/killer 1) [NCBI Gene 578] {aka BAK, BAK-LIKE, BCL2L7, CDN1}, CASP1 (caspase 1) [NCBI Gene 834] {aka ICE, IL1BC, P45}, CHUK (component of inhibitor of nuclear factor kappa B kinase complex) [NCBI Gene 1147] {aka BPS2, IKBKA, IKK-1, IKK-alpha, IKK1, IKKA}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, EEF1A2 (eukaryotic translation elongation factor 1 alpha 2) [NCBI Gene 1917] {aka DEE33, EEF1AL, EF-1-alpha-2, EF1A, EIEE33, HS1}, RIGI (RNA sensor RIG-I) [NCBI Gene 23586] {aka DDX58, RIG-I, RIG1, RLR-1, SGMRT2}, IFIH1 (interferon induced with helicase C domain 1) [NCBI Gene 64135] {aka AGS7, Hlcd, IDDM19, IMD95, MDA-5, MDA5}, IRF3 (interferon regulatory factor 3) [NCBI Gene 3661] {aka IIAE7}, NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548] {aka AGTAVPRL, AII, AVP, C1orf7, CIAS1, CLR1.1}, APOBEC3B (apolipoprotein B mRNA editing enzyme catalytic subunit 3B) [NCBI Gene 9582] {aka A3B, APOBEC1L, ARCD3, ARP4, DJ742C19.2, PHRBNL}, BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581] {aka BCL2L4}, UNG (uracil DNA glycosylase) [NCBI Gene 7374] {aka DGU, HIGM4, HIGM5, UDG, UNG1, UNG15}
- **Diseases:** Hypoxia (MESH:D000860), systemic lupus erythematosus (MESH:D008180), necrotic (MESH:D009336), metabolic disorders (MESH:D008659), SLIDINGWINDOW:4:20 (OMIM:615707), carcinogenesis (MESH:D063646), hypoxic (MESH:D002534), breast, bladder, cervical, and head and neck cancers (MESH:D001943), autoimmune diseases (MESH:D001327), neuronal damage (MESH:D009410), neuroinflammation (MESH:D000090862), toxicity (MESH:D064420), Cancer (MESH:D009369), Alzheimer's (MESH:D000544), mitochondrial disturbance (MESH:D028361), Parkinson's (MESH:D010300), viral infection (MESH:D014777), monocytic leukaemia (MESH:D007951), Inflammatory (MESH:D007249), neurodegeneration (MESH:D019636)
- **Chemicals:** calcium (MESH:D002118), ROS (MESH:D017382), DAPI (MESH:C007293), DMSO (MESH:D004121), CoCl2 (MESH:C018021), HCl (MESH:D006851), Tween (MESH:D011136), TBS (MESH:D013725), MitoTracker Red CMXRos (MESH:C107472), PFA (MESH:C003043), SYBR green (MESH:C098022), cobalt (MESH:D003035), CO2 (MESH:D002245), water (MESH:D014867), ATP (MESH:D000255), cytosines (MESH:D003596), Alexa Fluor 488 (MESH:C000711379), Bis-Tris (MESH:C026272), streptomycin (MESH:D013307), Ser (MESH:D012694), 7-AAD (MESH:C025942), Etoposide (MESH:D005047), EDTA (MESH:D004492), digitonin (MESH:D004072), PMSF (MESH:D010664), uracil (MESH:D014498), NP-40 (MESH:C010615), HEPES (MESH:D006531), Alexa Fluor 647 (MESH:C569686), phalloidin (MESH:D010590), oxygen (MESH:D010100), penicillin (MESH:D010406), NaCl (MESH:D012965), deoxycholic acid (MESH:D003840), methanol (MESH:D000432), proline (MESH:D011392), metal (MESH:D008670), A34055 (-)
- **Species:** Gallus gallus (bantam, species) [taxon 9031], Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090], Coturnix coturnix (Common quail, species) [taxon 9091]
- **Mutations:** C-to-G, A3A, C-to-T
- **Cell lines:** quail — Coturnix japonica (Japanese quail), Quail fibrosarcoma, Cancer cell line (CVCL_T464), QT6 — Coturnix japonica (Japanese quail), Quail fibrosarcoma, Cancer cell line (CVCL_3451), HEK-293T — Homo sapiens (Human), Transformed cell line (CVCL_0063), THP-1 — Homo sapiens (Human), Childhood acute monocytic leukemia, Cancer cell line (CVCL_0006), S2 — Drosophila melanogaster (Fruit fly), Spontaneously immortalized cell line (CVCL_Z232)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12926716/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12926716/full.md

## References

74 references — full list in the complete paper: https://tomesphere.com/paper/PMC12926716/full.md

---
Source: https://tomesphere.com/paper/PMC12926716